ClinicalTrials.gg
RecruitingNCT07938320Updated Nov 16, 2026

Vuse Pro Puffing Topography Study in Adult Smokers

An interventional study of FT254421 and FT25631 in Smoking and Tobacco, sponsored by RAI Services Company. Recruiting at 3 sites in United States. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by RAI Services Company (part of British American Tobacco) · Not applicable, Interventional, and Other

From the registry’s dates

  • Started Oct 2026; still recruiting 1 month later.
Updated Nov 16, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
21 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Smoking by British American Tobacco — 12 open to participants now, 12 under way, none of them phase 3. Smoking · British American Tobacco.

Planned enrollment
10th of 52
200 · median 70
Started
2026
with 10 others
No phase
52 of 55
12 open now
Primary completion
2027-01
later than 10 of 11 live
Registered
55th of 55
by date

Among the 55 studies in Smoking by British American Tobacco, this one is the 10th largest by planned enrollment of the 52 interventional ones that give a count, is one of 11 that started in 2026, is one of 52 with no phase, reaches primary completion later than 10 of the 11 other live ones, and was the 55th registered.

Smoking

1,513 studies on the registry are indexed under Smoking; 194 are open to participants now.

Browse Smoking studies →

Open to participants now

12 of the 55 studies in Smoking by British American Tobacco are open now, in 1 country. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 12 open studies →

Where they have run

Who these studies take

Of the 140 Smoking studies recruiting now, 74 (53%) set no upper age limit and 48 (34%) stop at 75 or younger; 3 take children under 18; 65 take healthy volunteers.

This study: 21 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Smoking by British American Tobacco, or all of them as a file.
02

Study summary

This is a multi-site, open-label, randomized study to measure puffing topography of generally healthy adult smokers of cigarettes when provided with an electronic nicotine delivery system over a 14-day period of product use.

Read the detailed description

This will be a multi-site, open-label, parallel design, four-arm, randomized cohort study to measure the puffing topography of generally healthy adult smokers of combustible cigarettes (CCs) when provided with an electronic nicotine delivery system (ENDS) over a 14-day product use period.

03

Conditions studied

  • Smoking
  • Tobacco

Keywords

  • Tobacco Harm Reduction
  • Smoking
  • Tobacco Use
  • Tobacco Smoking
04

Who can participate

Ages eligible
21 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to read, understand, and be willing to sign an form (ICF) and complete questionnaires written in English
  • Generally healthy males, females, intersex, or 'unknown', age 21-65 years (inclusive at the time of informed consent), verified with government-issued identification
  • All females and those who identify as "intersex" or "unknown" must have a negative pregnancy test at screening and affirm at the SEV that they are not pregnant or intending to become pregnant
  • Self-report currently smoking at least five CPD on smoking days in the past 30 days
  • Smoke CC on 15 or more of the past 30 days
  • Have smoked at least 100 factory-made filtered CC in their lifetime prior to SEV
  • Indicate a willingness to use ENDS
  • Agree to participate in the study and to abide by the study restrictions and requirements, including the use of the assigned Study IP, as described in the ICF
  • Agree not to allow any other person to use any product provided to them for use during this study

Exclusion criteria

Exclusion Criteria:

  • Females who self-report they are pregnant or breastfeeding or planning to become pregnant or start breastfeeding within the next 6 months from the study start date
  • Males who self-report they are not willing to use a barrier method of (e.g., a condom with spermicide) or refrain from donating sperm from the time of signing the ICF until the end of the study, unless they have undergone a vasectomy or are abstinent from heterosexual intercourse, or their female partner was not able to bear children
  • Females who self-report not using adequate methods to prevent pregnancy (Use of contraceptives or abstinence)
  • Individuals who self-report having pacemakers or other embedded electronic medical devices
  • Individuals who self-report having an unstable heart condition, severe hypertension, or diabetes
  • Individuals who self-report they are allergic/sensitive to cosmetics or fragrances or any ingredient listed in commercial e-cigarette products
  • Individuals who self-report they are sensitive to nicotine
  • Individuals who self-report physical or mental health
  • Individuals who have used ENDS, nicotine pouch, smokeless tobacco (i.e., chewing tobacco, snus, or snuff) products, heated tobacco products, or other combustible products and other oral nicotine products (tablets, gums, and lozenges) on 11 or more days in the past 30 days
  • Individuals who have used a nicotine replacement therapy (NRT) product or a prescription drug to help stop smoking (e.g., varenicline, bupropion) in the past 30 days
  • Individuals who are employed by a company that manufactures tobacco, ENDS, marketing or in ongoing litigation with a tobacco company
  • Individuals who self-report that they are planning to quit all nicotine products in the next three months
  • Individuals who are personally, have household members, or have close family or friends in litigation with a company that manufactures tobacco or ENDS products
  • Individuals who have taken part in a tobacco/nicotine research study in the past 30 days
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (estimated)

Study arms

  • Active comparator
    Device Two and NTNM

    FT25625 and Non-Tobacco Non-Menthol SKU (FT254421)

    Other: FT254421 · Other: FT25625

  • Active comparator
    Device Four and Tobacco SKU

    FT25629 and Tobacco SKU (FT25631)

    Other: FT25631 · Other: FT25629

  • Active comparator
    Device Four and Non-Tobacco Non-Menthol SKU

    FT25629 and NTNM SKU (FT254421)

    Other: FT254421 · Other: FT25629

  • Active comparator
    Device Four (Fixed) and Non-Tobacco Non-Menthol SKU

    FT25628 and NTNM SKU (FT254421)

    Other: FT254421 · Other: FT25628

Interventions

  • OtherFT254421

    Non-Tobacco Non-Mint/Menthol SKU

  • OtherFT25631

    Tobacco SKU

  • OtherFT25625

    Device Two

  • OtherFT25629

    Device Four

  • OtherFT25628

    Device Four (fixed)

06

What researchers measure

Primary outcomes

  1. To descriptively characterize the user puffing topography measures (Session and Puff characteristics) of primary CC smokers when using one of two Vuse Pro Power Units and one of two e-liquid cartridges with the same nicotine concentration.

    Time frame: 14 days

Secondary outcomes

  1. Evaluate Participant Demographics

    Time frame: 14 days

  2. Frequency of Use of Different Power Settings

    To descriptively evaluate the frequency of use of different Vuse Pro Power Unit power settings throughout the 14-day study period.

    Time frame: 14 days

  3. Characterization of Device Mishandling and Misuse

    Survey questionnaire at end of study.

    Time frame: 14 days

  4. Characterize use of other commercially available Vuse Pro Products

    Through survey questionnaire.

    Time frame: 14 days

  5. Cigarette Consumption and use of other TNPs

    Time frame: 14 days

  6. Product Liking

    Through survey questionnaire.

    Time frame: 14 days

  7. Purchase Intent of Study IP

    Through survey questionnaire.

    Time frame: 14 days

07

Study locations

3 of 3 sites recruiting
  • Sago Phoenix
    Phoenix, Arizona 85016, United States
    Recruiting
  • WAC
    Doral, Florida 33178, United States
    Recruiting
  • L&E Research Tampa
    Tampa, Florida 33634, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2026 (actual). Primary completion is estimated for Jan 2027, 3 months after the start.

Of 55 industry-sponsored interventional studies with no phase under Smoking, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's planned 3 months is close to that.

Counting every sponsor, half of 457 studies reached it within 23 months; a quarter within 8 and three quarters within 40.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 21, 2026
First posted
Nov 16, 2026
StartActual
Oct 15, 2026
Primary completionEst.
Jan 2027
CompletionEst.
Jan 2027
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07938320
Responsible party
Sponsor
First posted
Nov 16, 2026
Start date
Oct 15, 2026
Primary completion
Jan 2027 (estimated)
Completion
Jan 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Montgomery Hedgecock
Contact
montgomery_hedgecock@rjrt.com
336-741-3761

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion